Javascript must be enabled to continue!
The Dynamics of Seizures After Microsurgical Treatment of Brain AVMs in Patients with Symptomatic Epilepsy: A Single-Center Experience over 10 Years
View through CrossRef
Background and Objectives: Arteriovenous malformations (AVMs) are abnormal connections between arteries and veins, lacking a normal capillary network. Seizures are a common clinical manifestation in patients with brain AVMs, ranking as the second most frequent presentation. The objective of this study was to evaluate the dynamics of seizure activity in patients with brain AVMs following surgical treatment. Materials and Methods: This study included 27 patients with brain AVMs who underwent microsurgical AVM resection for symptomatic epilepsy. All surgical interventions were performed at JSC “National Centre for Neurosurgery” between 2008 and 2020. Results: Over an average follow-up period of 98.07 ± 45.6 months, 82 patients with brain AVMs underwent open microsurgical resection at the National Centre for Neurosurgery. Among them, 27 patients presented with seizures and had complete follow-up information, qualifying them for inclusion in this study. The participants had a mean age of 32.59 ± 9.06 years, with 13 of them being women. The Spetzler–Martin grading system was used to classify the AVMs: 6 patients had grade 1, 13 had grade 2, 7 had grade 3, and 1 had grade 4. More than half of the patients experienced generalized seizures. Microsurgical removal of the AVMs resulted in seizure remission for all patients. Only one patient experienced postoperative hemorrhage during the follow-up period. Additionally, one patient developed acute postoperative anemia, which resolved with a favorable outcome. Conclusions: Microsurgical resection of brain AVMs, when performed with careful patient selection, leads to a significant reduction in seizure activity. It is a safe and effective treatment option for symptomatic epilepsy associated with brain AVMs.
Title: The Dynamics of Seizures After Microsurgical Treatment of Brain AVMs in Patients with Symptomatic Epilepsy: A Single-Center Experience over 10 Years
Description:
Background and Objectives: Arteriovenous malformations (AVMs) are abnormal connections between arteries and veins, lacking a normal capillary network.
Seizures are a common clinical manifestation in patients with brain AVMs, ranking as the second most frequent presentation.
The objective of this study was to evaluate the dynamics of seizure activity in patients with brain AVMs following surgical treatment.
Materials and Methods: This study included 27 patients with brain AVMs who underwent microsurgical AVM resection for symptomatic epilepsy.
All surgical interventions were performed at JSC “National Centre for Neurosurgery” between 2008 and 2020.
Results: Over an average follow-up period of 98.
07 ± 45.
6 months, 82 patients with brain AVMs underwent open microsurgical resection at the National Centre for Neurosurgery.
Among them, 27 patients presented with seizures and had complete follow-up information, qualifying them for inclusion in this study.
The participants had a mean age of 32.
59 ± 9.
06 years, with 13 of them being women.
The Spetzler–Martin grading system was used to classify the AVMs: 6 patients had grade 1, 13 had grade 2, 7 had grade 3, and 1 had grade 4.
More than half of the patients experienced generalized seizures.
Microsurgical removal of the AVMs resulted in seizure remission for all patients.
Only one patient experienced postoperative hemorrhage during the follow-up period.
Additionally, one patient developed acute postoperative anemia, which resolved with a favorable outcome.
Conclusions: Microsurgical resection of brain AVMs, when performed with careful patient selection, leads to a significant reduction in seizure activity.
It is a safe and effective treatment option for symptomatic epilepsy associated with brain AVMs.
Related Results
Ictogenesis
Ictogenesis
*Michel Le Van Quyen, †Pascale Quilichini, †Yehezkel Ben‐Ari, †Christophe Bernard, and †Henri Gozlan ( *Neurodynamics Group, LENA‐CNRS UPR640, Hôpital de la Salpêtrière, Paris , an...
Brain Organoids, the Path Forward?
Brain Organoids, the Path Forward?
Photo by Maxim Berg on Unsplash
INTRODUCTION
The brain is one of the most foundational parts of being human, and we are still learning about what makes humans unique. Advancements ...
Diagnostic Methods, Treatment Modalities, and Follow-up of Extracranial Arteriovenous Malformations
Diagnostic Methods, Treatment Modalities, and Follow-up of Extracranial Arteriovenous Malformations
Objective. Arteriovenous malformations (AVMs) are an uncommon vascular pathology that remains challenging to accurately diagnose and successfully treat. This study introduces a nov...
Portrait of Epilepsy on the Canvas of Global Health
Portrait of Epilepsy on the Canvas of Global Health
Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD Epilepsy Collabora...
DECISION MAKING IN EPILEPTIC AVMS
DECISION MAKING IN EPILEPTIC AVMS
While there is no doubt about the need for surgical treatment of a ruptured arteriovenous malformation (AVM), the decision to surgically treat a patient presenting solely with seiz...
Neuropathology in the North American sudden unexpected death in epilepsy registry
Neuropathology in the North American sudden unexpected death in epilepsy registry
Abstract
Sudden unexpected death in epilepsy is the leading category of epilepsy-related death and the underlying mechanisms are incompletely understood. Risk factor...
Epilepsy in children and anesthesia
Epilepsy in children and anesthesia
Epilepsy, also called seizure disorder, is the most common childhood brain disorder in the United States. The aetiology of epilepsy in children is multifactorial with congenital, m...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

